Balyasny Asset Management
ZNTL icon

Balyasny Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Balyasny Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.08M – 3304
2022
Q3 		$1.08M Buy
+50,000
New +$1.37M ﹤0.01% 1763

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's ZNTL Position: Q4 2025 in Review

Balyasny Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 1,185,521 shares — an estimated $1.79M sold.

Balyasny Asset Management first reported a position in ZNTL in Q1 2023 and held it in 8 quarters. The position peaked at $1.79M in Q3 2025. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Balyasny Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 1,185,521 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $1.79M.
  • Balyasny Asset Management first reported a position in Zentalis Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Balyasny Asset Management's Zentalis Pharmaceuticals position peaked at $1.79M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.